Literature DB >> 14742228

Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.

Marc Wirden1, Constance Delaugerre, Anne Genevieve Marcelin, Nadine Ktorza, Hocine Ait Mohand, Stephanie Dominguez, Luminita Schneider, Jade Ghosn, Michele Pauchard, Dominique Costagliola, Christine Katlama, Vincent Calvez.   

Abstract

The dynamics of mutations associated with resistance to antiretroviral drugs were analyzed after cessation of therapy. The results showed that the kinetics of the shift to wild-type amino acid residues were significantly faster for protease inhibitors, intermediate for nonnucleoside reverse transcriptase inhibitors, and slower for nucleoside reverse transcriptase inhibitors.

Mesh:

Substances:

Year:  2004        PMID: 14742228      PMCID: PMC321535          DOI: 10.1128/AAC.48.2.644-647.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  AIDS. Boosting immunity to HIV--can the virus help?

Authors:  B Autran; G Carcelain
Journal:  Science       Date:  2000-11-03       Impact factor: 47.728

2.  Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.

Authors:  C Delaugerre; M A Valantin; M Mouroux; M Bonmarchand; G Carcelain; C Duvivier; R Tubiana; A Simon; F Bricaire; H Agut; B Autran; C Katlama; V Calvez
Journal:  AIDS       Date:  2001-11-09       Impact factor: 4.177

3.  Control of HIV despite the discontinuation of antiretroviral therapy.

Authors:  J Lisziewicz; E Rosenberg; J Lieberman; H Jessen; L Lopalco; R Siliciano; B Walker; F Lori
Journal:  N Engl J Med       Date:  1999-05-27       Impact factor: 91.245

4.  Immune control of HIV-1 after early treatment of acute infection.

Authors:  E S Rosenberg; M Altfeld; S H Poon; M N Phillips; B M Wilkes; R L Eldridge; G K Robbins; R T D'Aquila; P J Goulder; B D Walker
Journal:  Nature       Date:  2000-09-28       Impact factor: 49.962

5.  Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response.

Authors:  Steven G Deeks; Robert M Grant; Terri Wrin; Ellen E Paxinos; Teri Liegler; Rebecca Hoh; Jeff N Martin; Christos J Petropoulos
Journal:  AIDS       Date:  2003-02-14       Impact factor: 4.177

6.  Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy.

Authors:  H L Devereux; M Youle; M A Johnson; C Loveday
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

7.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Authors:  V Miller; C Sabin; K Hertogs; S Bloor; J Martinez-Picado; R D'Aquila; B Larder; T Lutz; P Gute; E Weidmann; H Rabenau; A Phillips; S Staszewski
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

8.  Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy.

Authors:  M Birk; V Svedhem; A Sönnerborg
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

9.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

10.  Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.

Authors:  J Izopet; P Massip; C Souyris; K Sandres; B Puissant; M Obadia; C Pasquier; E Bonnet; B Marchou; J Puel
Journal:  AIDS       Date:  2000-10-20       Impact factor: 4.177

View more
  3 in total

1.  Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study.

Authors:  Ume L Abbas; Robert L Glaubius; Yajun Ding; Gregory Hood
Journal:  PLoS One       Date:  2019-07-03       Impact factor: 3.240

2.  Crippling HIV one mutation at a time.

Authors:  Todd M Allen; Marcus Altfeld
Journal:  J Exp Med       Date:  2008-05-05       Impact factor: 14.307

3.  Multidrug-resistant HIV viral rebound during early syphilis: a case report.

Authors:  Andrea Giacomelli; Valeria Micheli; Dario Cattaneo; Alessandro Mancon; Cristina Gervasoni
Journal:  BMC Infect Dis       Date:  2020-04-07       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.